New Locus for Skin Intrinsic Fluorescence in Type 1 Diabetes Also Associated With Blood and Skin Glycated Proteins

Delnaz Roshandel,Ronald Klein,Barbara E.K. Klein,Bruce H.R. Wolffenbuttel,Melanie M. van der Klauw,Jana V. van Vliet-Ostaptchouk,Gil Atzmon,Danny Ben-Avraham,Jill P. Crandall,Nir Barzilai,Shelley B. Bull,Angelo J. Canty,S. Mohsen Hosseini,Linda T. Hiraki,John Maynard,David R. Sell,Vincent M. Monnier,Patricia A. Cleary,Barbara H. Braffett,the DCCT/EDIC Research Group,Andrew D. Paterson,
DOI: https://doi.org/10.2337/db15-1484
IF: 7.7
2016-04-12
Diabetes
Abstract:Skin fluorescence (SF) noninvasively measures advanced glycation end products (AGEs) in the skin and is a risk indicator for diabetes complications. N-acetyltransferase 2 (NAT2) is the only known locus influencing SF. We aimed to identify additional genetic loci influencing SF in type 1 diabetes (T1D) through a meta-analysis of genome-wide association studies (N = 1,359) including Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). A locus on chromosome 1, rs7533564 (P = 1.9 × 10−9), was associated with skin intrinsic fluorescence measured by SCOUT DS (excitation 375 nm, emission 435–655 nm), which remained significant after adjustment for time-weighted HbA1c (P = 1.7 × 10−8). rs7533564 was associated with mean HbA1c in meta-analysis (P = 0.0225), mean glycated albumin (P = 0.0029), and glyoxal hydroimidazolones (P = 0.049), an AGE measured in skin biopsy collagen, in DCCT. rs7533564 was not associated with diabetes complications in DCCT/EDIC or with SF in subjects without diabetes (nondiabetic [ND]) (N = 8,721). In conclusion, we identified a new locus associated with SF in T1D subjects that did not show similar effect in ND subjects, suggesting a diabetes-specific effect. This association needs to be investigated in type 2 diabetes.
endocrinology & metabolism
What problem does this paper attempt to address?